文献速递心脑血管急症重症综合管理与镇静镇痛

机械取栓治疗中或远端动脉闭塞性缺血性卒中:DISCOUNT随机临床试验

Mechanical Thrombectomy in Ischemic Stroke With a Medium or Distal Arterial Occlusion: The DISCOUNT Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01
一句话结论对于中或远端血管闭塞所致急性缺血性卒中,取栓联合药物治疗未提高3个月良好临床结局率,且症状性颅内出血更常见。

DISCOUNT试验在法国22个卒中中心纳入244例中或远端血管闭塞所致急性缺血性卒中患者,随机接受取栓联合药物治疗(n=123)或单纯药物治疗(n=121)。3个月良好临床结局(改良Rankin量表0-2分)取栓组62% vs 对照组68%(OR 0.73,95%CI 0.40-1.31;P=0.29;校正绝对差-6.8%,95%CI -19.4%至5.7%)。实际接受取栓的100例患者症状性颅内出血发生率11% vs 未取栓者3%(P=0.008),蛛网膜下腔出血13% vs 2%(P<0.001),栓子迁移5% vs 1%(P=0.04)。两组3个月死亡率无显著差异(6% vs 8%;P=0.49)。试验因无效及取栓组症状性颅内出血增加,经数据与安全监察委员会建议提前终止。

要点

  • 中或远端血管闭塞所致急性缺血性卒中,取栓联合药物治疗相比单纯药物治疗未提高3个月良好临床结局率(62% vs 68%;OR 0.73,95%CI 0.40-1.31;P=0.29)。
  • 实际接受取栓的100例患者症状性颅内出血发生率高于未取栓者(11% vs 3%,P=0.008),蛛网膜下腔出血(13% vs 2%,P<0.001)和栓子迁移(5% vs 1%,P=0.04)也更常见。
  • 两组3个月死亡率无显著差异(6% vs 8%;P=0.49)。
  • 试验因无效及取栓组症状性颅内出血增加,经数据与安全监察委员会建议后提前终止,计划入组488例,实际随机244例。
  • 取栓组123例中100例(81%)实际接受取栓,对照组121例均未接受取栓;217例(89%)完成随访。

适用人群与场景

  • 成人急性缺血性卒中患者,由原发性孤立的中或远端血管闭塞所致,症状发作8小时内或最后已知正常24小时内且液体衰减反转恢复成像未见高信号。
  • 研究在法国22个卒中中心进行,随机分组为取栓联合药物治疗(n=123)或单纯药物治疗(n=121)。

诊断标准与关键阈值

  • 中或远端血管闭塞(MDVO)定义为原发性且孤立的闭塞。
  • 主要终点良好临床结局定义为3个月时改良Rankin量表评分0-2分,由独立盲法评估者评定。

红旗征与不能漏的情况

  • 取栓后症状性颅内出血发生率11% vs 3%(P=0.008),蛛网膜下腔出血13% vs 2%(P<0.001),栓子迁移5% vs 1%(P=0.04),均在实际接受取栓的100例患者中高于未取栓者。

研究设计与关键结果

  • 研究类型:随机临床试验,法国22个卒中中心,2021年11月至2025年4月,计划入组488例,实际随机244例(取栓组123例,对照组121例);中位年龄75岁(IQR 67-81),56%男性,中位NIHSS评分8分(IQR 6-12)。
  • 干预与对照:取栓联合药物治疗 vs 单纯药物治疗;取栓组123例中100例(81%)实际接受取栓,对照组121例中0例接受取栓;217例(89%)完成随访。
  • 主要终点:3个月良好临床结局取栓组72/116例(62%)vs 对照组81/119例(68%)(OR 0.73,95%CI 0.40-1.31;P=0.29;校正绝对差-6.8%,95%CI -19.4%至5.7%)。
  • 关键次要终点与不良事件:症状性颅内出血在实际接受取栓的100例中11% vs 未取栓者3%(P=0.008);蛛网膜下腔出血13% vs 2%(P<0.001);栓子迁移5% vs 1%(P=0.04);3个月死亡率取栓组6% vs 对照组8%(P=0.49),无显著差异。
  • 试验因无效及取栓组症状性颅内出血增加,经数据与安全监察委员会建议提前终止。

证据类型、等级与局限

  • 证据类型:随机临床试验(RCT)。
  • 试验注册号:ClinicalTrials.gov NCT05030142。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于中或远端血管闭塞所致急性缺血性卒中,取栓联合药物治疗未较单纯药物治疗提高3个月良好临床结局率,且实际接受取栓者症状性颅内出血、蛛网膜下腔出血和栓子迁移发生率更高;原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Evidence regarding efficacy and safety of thrombectomy in acute ischemic stroke (AIS) due to medium or distal vessel occlusions (MDVOs) is lacking.

OBJECTIVE: To evaluate the benefit of thrombectomy, in addition to medical treatment over medical treatment alone, in patients with an AIS related to a primary and isolated MDVO.

DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial conducted at 22 stroke centers in France from November 2021 to April 2025, with planned enrollment of 488 patients. The trial has been stopped after the planned interim analysis on the recommendation of the data and safety monitoring board for futility and increased rate of symptomatic intracranial hemorrhage with thrombectomy. Eligible adult patients had an AIS due to a primary MDVO within 8 hours of symptom onset or within 24 hours of last seen well if no hyperintense signal was present on fluid-attenuated inversion recovery imaging.

INTERVENTION: Thrombectomy in addition to medical treatment (n = 123) or medical treatment alone (n = 121).

MAIN OUTCOMES AND MEASURES: The primary end point was a good clinical outcome at 3 months, defined as a modified Rankin Scale score of 0 to 2, assessed by an independent, blinded assessor. Secondary end points included mortality rate at 3 months and adverse and serious adverse events.

RESULTS: Of the 244 patients randomized (median age, 75 years [IQR, 67-81]; 56% male; median National Institutes of Health Stroke Scale score, 8 [IQR, 6-12]), 100 of the 123 patients in the thrombectomy group (81%) received thrombectomy and none of the 121 patients in the control group received thrombectomy; 217 (89%) completed follow-up. At 3 months, 72 of 116 patients (62%) in the thrombectomy group had a good clinical outcome vs 81 of 119 patients (68%) in the control group (odds ratio, 0.73 [95% CI, 0.40-1.31]; P = .29; adjusted absolute difference, -6.8% [95% CI, -19.4% to 5.7%]). The incidence of symptomatic intracranial hemorrhages was higher among the 100 patients who actually received thrombectomy than in those who did not (11% vs 3%, P = .008), as was incidence of subarachnoid hemorrhages (13% vs 2%, P < .001) and embolus migration (5% vs 1%, P = .04). Mortality rate did not significantly differ between the 2 groups (6% vs 8%; P = .49).

CONCLUSIONS AND RELEVANCE: Thrombectomy did not lead to a higher rate of good clinical outcome at 3 months compared with medical treatment alone in patients with acute ischemic stroke related to an MDVO. Hemorrhagic complications were more frequent after thrombectomy.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05030142.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Clarençon F, Bala F, Baptiste A, et al. Mechanical Thrombectomy in Ischemic Stroke With a Medium or Distal Arterial Occlusion: The DISCOUNT Randomized Clinical Trial. JAMA. 2026. PMID: 42485024. doi:10.1001/jama.2026.8977

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。